

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 56

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 56

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 56

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Internacionales Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

alcaftadinum

alcaftadine

11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-imidazo=[2,1-b][3]benzazepine-3-carbaldehyde


alcaftadine

11-(1-méthylpipéridin-4-ylidène)-6,11-dihydro-5H-imidazo=[2,1-b][3]benzazépine-3-caraldéhyde

alcaftadina

11-(1-metilpiperidin-4-ilideno)-6,11-dihidro-5H-imidazo=[2,1-b][3]benzazepina-3-carbaldehído

C₁₉H₂₁N₃O



amibegronum

amibegron

ethyl {[[(7S)-7-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate


amibégron

[[[(7S)-7-[[[(2R)-2-(3-chlorophényl)-2-hydroxyéthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]acétate d'éthyle

amibegrón

[[[(7S)-7-[[[(2R)-2-(3-clorofenil)-2-hidroxietil]amino]-5,6,7,8-tetrahidronaftalen-2-il]oxi]acetato de etilo

C₂₂H₂₆ClNO₄



antithrombinum alfa

antithrombin alfa

human antithrombin-III from the milk of transgenic goats
(glycoform alfa)

antithrombine alfa

antithrombine-III humaine extraite du lait de chèvre transgénique
(glycoforme alfa)

antitrombina alfa

antitrombina-III humana extraída de la leche de cabra transgénica
(glicoforma alfa)C₂₁₉₁H₃₄₅₁N₅₈₃O₆₅₆S₁₈

HGSPVDICTA	KPRDIPMNPM	CIYRSPEKKA	TEDEGSEQKI
PEATNRRVWE	LSKANSRFAT	TFYQHLADSK	NDNDNIFLSP
LSISTAFAMT	KLGACNDTLQ	QLMEVFKFDT	ISEKTSQIHI
FFFAKLNCRL	YRKANKSSKL	VSANRLFGDK	SLTF [*] NETYQD
ISELVYGAKL	QPLDFKENAE	QSRAAINKWV	SNKTEGRITD
VIPSEAINEL	TVLVLVNTIY	FKGLWKSFKS	PENTRKELFY
KADGESCSAS	MMYQEGKFRY	RRVAEGTQVL	ELPFKGDDIT
MVLILPKPEK	SLAKVEKELT	PEVLQEWLDE	LEEMMLVVHM
PRFRIEDGFS	LKEQLQDMGL	VDLFSPEKSK	LPGIVAEGRD
DLYVSDAFHK	AFLEVNEEGS	EAAASTAVVI	AGRSLNPNRV
TFKANRPFLV	FIREVPLNTI	IFMGRVANPC	VK

* glycosylation sites
 * sites de glycosylation
 * posiciones de glicosilación

apadenosonum


apadenoson

methyl *trans*-4-[3-[6-amino-9-(*N*-ethyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-ynyl]cyclohexanecarboxylate

apadénoson

trans-4-[3-[6-amino-9-(*N*-éthyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-ynyl]cyclohexanecarboxylate de méthyle

apadenosón

trans-4-[3-[6-amino-9-(*N*-etil-β-D-ribofuranosiluronamida)-9*H*-purin-2-il]prop-2-inil]ciclohexanocarboxilato de metiloC₂₃H₃₀N₆O₆

aplavirocum


aplaviroc

4-(4-(((3*R*)-1-butyl-3-[(*R*)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl)methyl)phenoxy)benzoic acid

aplaviroc

acide 4-[4-[[[(3*R*)-1-butyl-3-[(*R*)-cyclohexylhydroxyméthyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undéc-9-yl]méthyl]phénoxy]benzoïque

aplaviroc

ácido 4-[4-[[[(3*R*)-1-butil-3-[(*R*)-ciclohexilhidroximetil]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-il]metil]fenoxi]benzoicoC₃₃H₄₃N₃O₆**avosentanum**


avosentan

N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide

avosentan

N-[6-méthoxy-5-(2-méthoxyphénoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-5-méthylpyridine-2-sulfonamide

avosentán

5-metil-*N*-[6-metoxi-5-(2-metoxifenoxi)-2-(piridin-4-il)pirimidin-4-il]piridina-2-sulfonamidaC₂₃H₂₁N₅O₅S**axitinibum**

axitinib


N-methyl-2-({3-[(1*E*)-2-(pyridin-2-yl)ethenyl]-1*H*-indazol-6-yl}sulfanyl)benzamide

axitinib

N-méthyl-2-[[3-[(1*E*)-2-(pyridin-2-yl)éthényl]-1*H*-indazol-6-yl]sulfanyl]benzamide

axitinib

N-metil-2-[[3-[(1*E*)-2-(piridin-2-il)etenil]-1*H*-indazol-6-il]=sulfanil]benzamida

$C_{22}H_{18}N_4OS$ 

bosutinibum
bosutinib


4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

bosutinib

4-[(2,4-dichloro-5-méthoxyphényl)amino]-6-méthoxy-7-[3-(4-méthylpipérazin-1-yl)propoxy]quinoléine-3-carbonitrile

bosutinib

4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metilpiperazin-1-il)propoxi]quinolina-3-carbonitrilo

 $C_{26}H_{29}Cl_2N_5O_3$ 

brecanavirum
brecanavir



(3*R*,3*aS*,6*aR*)-hexahydrofurano[2,3-*b*]furan-3-yl
[(2*S*,3*R*)-4-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate

brécanavir

[(1*S*,2*R*)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-méthylpropyl)amino]-2-hydroxy-1-[4-[(2-méthylthiazol-4-yl)méthoxy]benzyl]=propyl]carbamate de (3*R*,3*aS*,6*aR*)-hexahydrofuro[2,3-*b*]furan-3-yle

brecanavir

[(1*S*,2*R*)-3-[(1,3-benzodioxol-5-il)sulfonyl](2-metilpropil)amino]-2-hidroxi-1-[4-[(2-metiltiazol-4-il)metoxi]bencil]propil]carbamato de (3*R*,3*aS*,6*aR*)-hexahidrofuro[2,3-*b*]furan-3-ilo



capeserodum
capeserod



5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-
3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2(3*H*)-one

capésérode

5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-
3-[1-(2-phényléthyl)pipéridin-4-yl]-1,3,4-oxadiazol-2(3*H*)-one

capeserod

5-(8-amino-7-cloro-2,3-dihidro-1,4-benzodioxin-5-il)-
3-[1-(2-feniletíl)piperidin-4-il]-1,3,4-oxadiazol-2(3*H*)-ona



casopitantum
casopitant



(2*R*,4*S*)-4-(4-acetyl piperazin-1-yl)-*N*-[(1*R*)-1-[3,5-bis(trifluoromethyl)=
phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-*N*-methylpiperidine-
1-carboxamide

casopitant

(2*R*,4*S*)-4-(4-acétylpipérazin-1-yl)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)=
phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthylpipéridine-
1-carboxamide

casopitant

(2*R*,4*S*)-4-(4-acetilpiperazin-1-il)-*N*-[(1*R*)-1-[3,5-bis(trifluorometil)=
fenil]etil]-2-(4-fluoro-2-metilfenil)-*N*-metilpiperidin-1-carboxamida



celivaronum

celivarone


isopropyl 2-butyl-3-{4-[3-(dibutylamino)propyl]benzoyl}-1-benzofuran-5-carboxylate

célivarone

2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]benzofurane-5-carboxylate de 1-méthyléthyle

celivarona

2-butil-3-{4-[3-(dibutilamino)propil]benzoil]-1-benzofurano-5-carboxilato de isopropilo

C₃₄H₄₇NO₄**cevoglitazarum**


cevoglitazar

(2*R*)-1-[[4-({[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]=methoxy)phenyl]sulfonyl]-2,3-dihydro-1*H*-indole-2-carboxylic acid

cévoglitazar

acide (2*R*)-1-[[4-[[[5-méthyl-2-[4-(trifluorométhyl)phényl]oxazol-4-yl]=méthoxy]phényl]sulfonyl]-2,3-dihydro-1*H*-indole-2-carboxylique

cevoglitazar

ácido (2*R*)-1-[[4-[[[5-metil-2-[4-(trifluorometil)fenil]oxazol-4-il]metoxi]fenil]sulfonyl]-2,3-dihidro-1*H*-indol-2-carboxílicoC₂₇H₂₁F₃N₂O₆S**darapladibum**

darapladib


N-[2-(diethylamino)ethyl]-2-[2-{{[4-(4-fluorophenyl)methyl]sulfonyl}-4-oxo-4,5,6,7-tetrahydro-1*H*-cyclopentapyrimidin-1-yl)}-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide

darapladib

N-[2-(diéthylamino)éthyl]-2-[2-[[4-(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tétrahydro-1*H*-cyclopentapyrimidin-1-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

darapladib

N-[2-(dietilamino)etil]-2-[2-[[4-(4-fluorobencil)sulfanil]-4-oxo-4,5,6,7-tetrahidro-1*H*-ciclopentapirimidin-1-il]-*N*-[[4'-(trifluorometil)=bifenil-4-il]metil]acetamida

$C_{36}H_{38}F_4N_4O_2S$ 

dasatinibum
dasatinib


N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

dasatinib

N-(2-chloro-6-méthylphényl)-2-[[6-[4-(2-hydroxyéthyl)pipérazin-1-yl]-2-méthylpyrimidin-4-yl]amino]thiazole-5-carboxamide

dasatinib

N-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietyl)piperazin-1-il]-2-metilpirimidin-4-il]amino]tiazol-5-carboxamida

 $C_{22}H_{26}ClN_7O_2S$ 

denaglipitinum
denaglipitin


(2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile

dénaglipatine

(2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorophényl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile

denaglipatina

(2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorofenil)propanoil]-4-fluoropirrolidina-2-carbonitrilo

 $C_{20}H_{18}F_3N_3O$ 

denosumabum*

denosumab

immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor)) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer

dénosumab

immunoglobuline G2, anti-(11^{ème} membre de la superfamille des ligands du facteur de nécrose tumorale (TNF) humain (facteur de différenciation de l'ostéoclaste)), dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal humain AMG162

denosumab

immunoglobulina G2, anti-(miembro n° 11 de la superfamilia de ligandos del factor de necrosis tumoral (TNF) humano (factor de diferenciación de osteoclastos)), dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano AMG162

C₆₄₀₄H₉₉₀₈N₁₇₂₄O₂₀₀₄S₅₀**dexamethasoni cipeccilas**

dexamethasone cipeccilate


9-fluoro-11β-hydroxy-16α-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl 21-cyclohexanecarboxylate 17-cyclopropanecarboxylate

cipéccilate de dexaméthasone

21-cyclohexanecarboxylate et 17-cyclopropanecarboxylate de 9-fluoro-11β-hydroxy-16α-méthyl-3,20-dioxoprégna-1,4-diène-17,21-diyle

cipeccilato de dexametasona

17-ciclopropanocarboxilato 9-fluoro-11β-hidroxi-16α-metil-3,20-dioxopregna-1,4-dieno-17,21-diil 21-ciclohexanecarboxilato

C₃₃H₄₃FO₇**diaplasininum**

diaplasinin


1-benzyl-3-pentyl-2-[6-[(1*H*-tetrazol-5-yl)methoxy]naphthalen-2-yl]-1*H*-indole

diaplasinine

1-benzyl-3-pentyl-2-[6-(1*H*-tétrazol-5-ylméthoxy)naphtalén-2-yl]-1*H*-indole

diaplasinina

1-bencil-3-pentil-2-[6-[(1*H*-tetrazol-5-il)metoxi]naftalen-2-il]-1*H*-indol

C₃₂H₃₁N₅O

dilopetinum
dilopetine


2-[(2-méthyl-1*H*-pyrazol-3-yl)(thiophén-2-yl)méthoxy]-*N,N*-diméthylethanamine

dilopétine

N,N-diméthyl-2-[(*RS*)-(1-méthyl-1*H*-pyrazol-5-yl)(thiophén-2-yl)=méthoxy]éthanamine

dilopetina

2-[(2-metil-1*H*-pirazol-3-il)(tiofen-2-il)metoxi]-*N,N*-dimetiletanamina

C₁₃H₁₉N₃OS

disomotidum
disomotide

[186-L-methionine]melanocyte protein Pmel 17 (human melanoma-associated ME20 antigen)-(185-193)-peptide

disomotide

[186-L-méthionine]protéine Pmel 17 du mélanocyte humain (antigène ME20 associé au mélanome humain)-(185-193)-peptide

disomotida

[186-L-metionina]proteína Pmel 17 de melanocitos humanos (antígeno ME20 asociado al melanoma humano)-(185-193)-péptido

C₄₇H₇₄N₁₀O₁₄S

H-Ile—Met—Asp—Gln—Val—Pro—Phe—Ser—Val—OH

dutacatibum
dutacatib

N-[(2-cyano-4-[(2,2-dimethylpropyl)amino]pyrimidin-5-yl)methyl]-4-(4-methylpiperazin-1-yl)benzamide

dutacatib

N-[[2-cyano-4-[(2,2-diméthylpropyl)amino]pyrimidin-5-yl]méthyl]-4-(4-méthylpipérazin-1-yl)benzamide



dutacatib

N-[[2-ciano-4-[(2,2-dimetilpropil)amino]pirimidin-5-il]metil]-4-(4-metilpiperazin-1-il)benzamida

eltrombopagum
eltrombopag

eltrombopag

eltrombopag

 $C_{23}H_{31}N_7O$ 3'-{[(2*Z*)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4*H*-pyrazol-4-ylidene]diazanyl]-2'-hydroxybiphenyl-3-carboxylic acidacide 3'-{[(2*Z*)-2-[1-(3,4-diméthylphényl)-3-méthyl-5-oxo-1,5-dihydro-4*H*-pyrazol-4-ylidène]diazanyl]-2'-hydroxybiphényl-3-carboxyliqueácido 3'-{[(2*Z*)-2-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-dihidro-4*H*-pirazol-4-ilideno]diazanil]-2'-hidroxibifenil-3-carboxílico $C_{25}H_{22}N_4O_4$ **eprodisatum**
eprodisate


éprodisate

eprodisato

propane-1,3-disulfonic acid

acide propane-1,3-disulfonique


ácid propano-1, 3-disulfónico

 $C_3H_8O_6S_2$ **fimasartanum**
fimasartan

fimasartan

fimasartán

2-({2-butyl-4-methyl-6-oxo-1-[[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,6-dihydropyrimidin-5-yl})-*N,N*-dimethylthioacetamide2-[2-butyl-4-méthyl-6-oxo-1-[[2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-1,6-dihydropyrimidin-5-yl]-*N,N*-diméthylthioacétamide2-({2-butil-4-metil-6-oxo-1-[[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil]-1,6-dihidropirimidin-5-il})-*N,N*-dimetiltioacetamida

C₂₇H₃₁N₇OS**fosaprepitantum**


fosaprepitant

(3-[[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl]phosphonic acid

fosaprépitant

acide [3-[[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3-(4-fluorophényl)morpholin-4-yl]méthyl]-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl]phosphonique

fosaprepitant

ácido [3-[[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi]-3-(4-fluorofenil)morfolin-4-il]metil]-5-oxo-4,5-dihidro-1*H*-1,2,4-triazol-1-il]fosfónicoC₂₃H₂₂F₇N₄O₆P**fospropofolum**

fospropofol


dihydrogen (2,6-diisopropylphenoxy)methyl phosphate

fospropofol

dihydrogénophosphate de [2,6-bis(1-méthyléthyl)phénoxy]méthyle

fospropofol

dihidrógenofosfato de [2,6-bis(1-metiletil)fenoxi]metilo

C₁₃H₂₁O₅P**gabapentinum enacarbilum**


gabapentin enacarbil

(1-[[[[(1*RS*)-1-[(2-methylpropanoyl)oxy]ethoxy]carbonyl]amino]=methyl]cyclohexyl]acetic acid

gabapentine enacarbil

acide [1-[[[[(1*RS*)-1-[(2-méthylpropanoyl)oxy]éthoxy]carbonyl]=amino]méthyl]cyclohexyl]acétique


gabapentina enacarbilo

ácido (1-[[[(1*RS*)-1-[(2-metilpropanoil)oxi]etoxi]carbonil]amino]=metil)ciclohexil)acético $C_{16}H_{27}NO_6$ goxalaplاديب
goxalaplاديب2-{2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidine-4-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide

goxalaplاديب

2-[2-[2-(2,3-difluorophényl)éthyl]-4-oxo-1,8-naphtyridin-1(4*H*)-yl]-*N*-[1-(2-méthoxyéthyl)pipéridin-4-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide


goxalaplاديب

2-[2-[2-(2,3-difluorofenil)etil]-4-oxo-1,8-naftiridin-1(4*H*)-il]-*N*-[1-(2-metoxietil)piperidin-4-il]-*N*-[[4'-(trifluorometil)bifenil-4-il]metil]acetamida $C_{40}H_{39}F_5N_4O_3$ incyclinidum
incyclinide(4*aS*,5*aR*,12*aS*)-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide

incyclinide

(4*aS*,5*aR*,12*aS*)-3,10,12,12*a*-tétrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

inciclinida

(4*aS*,5*aR*,12*aS*)-3,10,12,12*a*-tetrahidroxi-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahidrotetraceno-2-carboxamida $C_{19}H_{17}NO_7$ 

indantadolum


indantadol

2-[(2,3-dihydro-1*H*-inden-2-yl)amino]acetamide

indantadol

2-[(2,3-dihydro-1*H*-indén-2-yl)amino]acétamide

indantadol

2-[(2,3-dihidro-1*H*-inden-2-il)amino]acetamidaC₁₁H₁₄N₂O**ipilimumabum***

ipilimumab

immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human γ 1-chain), disulfide with human κ -chain, dimer

ipilimumab

immunoglobuline G1, anti-(antigène CTLA-4 humain), dimère du disulfure entre la chaîne γ 1 et la chaîne κ de l'anticorps monoclonal humain

ipilimumab

immunoglobulina G1, anti-(antígeno CTLA-4 humano), dímero del disulfuro entre la cadena γ 1 y la cadena κ del anticuerpo monoclonal humanoC₆₄₇₂H₉₉₇₂N₁₇₃₂O₂₀₀₄S₄₀**iratumumabum***

iratumumab

immunoglobulin G1, anti-(Tumor necrosis factor ligand superfamily member 8 (CD30 ligand)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer

iratumumab

immunoglobuline G1, anti-(8^{ème} membre de la superfamille des ligands du facteur de nécrose tumorale (TNF) humain), dimère du disulfure entre les chaînes lourde et légère de l'anticorps monoclonal humain NDX-060

iratumumab

immunoglobulina G1, anti-(8^º miembro de la superfamilia de ligandos del factor de necrosis tumoral (TNF) humano), dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano NDX-060C₆₃₅₈H₉₈₃₀N₁₆₈₂O₁₉₉₂S₃₈**larotaxelum**


larotaxel

1-hydroxy-9-oxo-5 β ,20-epoxy-7 β ,19-cyclotax-11-ene-2 α ,4,10 β ,13 α -tetrayl 4,10-diacetate 2-benzoate 13-[(2*R*,3*S*)-3-[(*tert*-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate]

larotaxel (-)-7,12a-diacétate, 1-benzoate et 4-[(2*R*,3*S*)-3-[(1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate] (1*S*,2*S*,4*S*,5*E*,7*R*,8*aR*,9*aS*,10*aR*,12*aS*,12*bR*)-2-hydroxy-5,13,13-triméthyl-8-oxo-1,3,4,7,8,9,9*a*,10,10*a*,12*b*-décahydro-2,6-méthano-2*H*-cyclodeca[3,4]cyclopropa[4,5]benzo[1,2-*b*]oxète-1,4,7,12*a* (12*H*)-tétrayle

larotaxel 4,10-diacetato 2-benzoato 13-[(2*R*,3*S*)-3-[(*tert*-butoxicarbonil)=amino]-2-hidroxi-3-fenilpropanoato] de 1-hidroxi-9-oxo-5β,20-epoxi-7β,19-ciclotax-11-eno-2α,4,10β,13α-tetraïlo

C₄₅H₅₃NO₁₄



lisdexamfetaminum

lisdexamfetamine

(2*S*)-2,6-diamino-*N*-[(2*S*)-1-phenylpropan-2-yl]hexanamide


lisdexamfétamine

(2*S*)-2,6-diamino-*N*-[(1*S*)-1-méthyl-2-phényléthyl]hexanamide

lisdexanfetamina

(2*S*)-2,6-diamino-*N*-[(1*S*)-2-fenil-1-metiletil]hexanamida

C₁₅H₂₅N₃O



lodenafili carbonas

lodenafil carbonate


bis(2-{4-[4-ethoxy-3-(1-méthyl-7-oxo-3-propyl-4,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)]phénylsulfonyl]piperazin-1-yl}éthyl)carbonate

lodénafil carbonate

carbonate de 2-[4-[[4-éthoxy-3-(1-méthyl-7-oxo-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)]phényl]sulfonyl]pipérazin-1-yl]éthyle

carbonato de lodenafilo

carbonato de bis(2-{4-[4-etoxi-3-(1-metil-7-oxo-3-propil-4,7-dihydro-1*H*-pirazolo[4,3-*d*]pirimidin-5-il)]fenilsulfonil]piperazin-1-il}etil)

C₄₇H₆₂N₁₂O₁₁S₂

masilukastum
masilukast


3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]carbamoyl]phenyl]=methyl]-1-methyl-*N*-[(2*R*)-4,4,4-trifluoro-2-methylbutyl]-1*H*-indole-5-carboxamide

masilukast

3-[2-méthoxy-4-[[[(2-méthylphényl)sulfonyl]carbamoyl]benzyl]-1-méthyl-*N*-[(2*R*)-4,4,4-trifluoro-2-méthylbutyl]-1*H*-indole-5-carboxamide

masilukast

1-metil-3-[[4-[[[(2-metilfenil)sulfonyl]carbamoyl]fenil]metil-2-metoksi]-*N*-[(2*R*)-4,4,4-trifluoro-2-metilbutil]-1*H*-indol-5-carboxamida

C₃₁H₃₂F₃N₃O₅S

mavacoxibum
mavacoxib


4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]=benzenesulfonamide

mavacoxib

4-[5-(4-fluorophényl)-3-(trifluorométhyl)-1*H*-pyrazol-1-yl]=benzènesulfonamide

mavacoxib

4-[5-(4-fluorofenil)-3-(trifluorometil)-1*H*-pirazol-1-il]=bencenesulfonamida

C₁₆H₁₁F₄N₃O₂S

nilotinibum
nilotinib


4-methyl-*N*-[3-(4-methyl-1*H*-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

nilotinib

4-méthyl-*N*-[3-(4-méthyl-1*H*-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

nilotinib

4-metil-*N*-[3-(4-metil-1*H*-imidazol-1-il)-5-(trifluorometil)fenil]-3-[[4-(piridin-3-il)pirimidin-2-il]amino]benzamida

C₂₈H₂₂F₃N₇O

nimotuzumabum*
nimotuzumab

immunoglobulin G1, anti-(humanized mouse monoclonal hR3 β1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hR3 κ-chain, dimer

nimotuzumab

immunoglobuline G1, anti-(récepteur du facteur de croissance des cellules de l'épiderme humain), dimère du disulfure entre la chaîne β1 et la chaîne κ de l'anticorps monoclonal de souris humanisé hR3

nimotuzumab

inmunoglobulina G1, anti-(receptor del factor de crecimiento de células de epidermis humana), dímero del disulfuro entre la cadena β1 y la cadena κ del anticuerpo monoclonal hR3 humanizado de ratón

C₆₅₆₆H₁₀₀₈₂N₁₇₄₆O₂₀₅₆S₄₀

obatoclaxum
obatoclax


2-{2-[(3,5-dimethyl-1*H*-pyrrol-2-yl)methylidene]-3-methoxy-2*H*-pyrrol-5-yl}-1*H*-indole

obatoclax

2-[2-[(3,5-diméthyl-1*H*-pyrrol-2-yl)méthylidène]-3-méthoxy-2*H*-pyrrol-5-yl]-1*H*-indole

obatoclax

2-[2-[(3,5-dimetil-1*H*-pirrol-2-il)metilideno]-3-metoxi-2*H*-pirrol-5-il]-1*H*-indol

C₂₀H₁₉N₃O

ocrelizumabum*
ocrelizumab

immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal 2H7 γ 1-chain), disulfide with human-mouse monoclonal 2H7 κ -chain, dimer

ocrélizumab

immunoglobuline G1, anti-(antigène CD20 humain), dimère du disulfure entre la chaîne γ 1 et la chaîne κ de l'anticorps monoclonal de souris humanisé 2H7

ocrelizumab

immunoglobulina G1, anti-(antígeno) CD20 humano dímero del disulfuro entre la cadena γ 1 del anticuerpo monoclonal 2H7 hombre-ratón, y la cadena- κ del anticuerpo monoclonal 2H7 hombre-ratón

C₆₄₉₄H₉₉₇₈N₁₇₁₈O₂₀₁₄S₄₆

oglemilastum
oglemilast


N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=amino]dibenzo[*b,f*]furan-1-carboxamide

oglémilast

N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=amino]dibenzo[*b,f*]furan-1-carboxamide

oglemilast

N-(3,5-dicloropiridin-4-il)-4-(difluorometoxi)-8-[(metilsulfonyl)=amino]dibenzo[*b,f*]furano-1-carboxamida

C₂₀H₁₃Cl₂F₂N₃O₅S

olaparibum
olaparib



4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2*H*)-one

olaparib

1-(cyclopropylcarbonyl)-4-[2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoyl]piperazine

olaparib

1-(ciclopropilcarbonil)-4-[2-fluoro-5-[(4-oxo-3,4-dihidroftalazin-1-il)metil]benzoil]piperazina



orvepitantum
orvepitant



(2*R*,4*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthyl-4-[(8*aS*)-6-oxohexahydro-1*H*-pyrrolo-[1,2-*a*]pyrazin-2-yl]piperidine-1-carboxamide

orvépitant

(2*R*,4*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthyl-4-[(8*aS*)-6-oxohexahydro-1*H*-pyrrolo-[1,2-*a*]pyrazin-2(1*H*)-yl]piperidine-1-carboxamide

orvepitant

(2*R*,4*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthyl-4-[(8*aS*)-6-oxohexahydro-1*H*-pyrrolo-[1,2-*a*]pyrazin-2(1*H*)-yl]piperidine-1-carboxamide



ovemotidum
ovemotide


[264-L-valine]melanocyte protein Pmel 17 (human melanoma-associated ME20 antigen)-(256-264)-peptide

ovémotide

[264-L-valine]protéine Pmel 17 du mélanocyte humain (antigène ME20 associé au mélanome humain)-(256-264)-peptide

ovemotida

[264-L-valina]proteína Pmel 17 de melanocitos humanos (antígeno ME20 asociado al melanoma humano)-(256-264)-péptido



ozarelixum
ozarelix


N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-*N*-methyl-L-tyrosyl-*N*⁶-carbamoyl-D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide

ozarélix

N-acétyl-3-(naphthalén-2-yl)-D-alanyl-4-chloro-D-phénylalanyl-3-(pyridin-3-yl)-D-alanyl-L-séryl-*N*-méthyl-L-tyrosyl-*N*⁶-carbamoyl-D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide

ozarelix

N-acetil-3-(naftalen-2-il)-D-alanil-4-cloro-D-fenilalanil-3-(piridin-3-il)-D-alanil-L-seril-*N*-metil-L-tirosil-*N*⁶-carbamoil-D-lisil-L-2-aminohexanoil-L-arginil-L-prolil-D-alaninamida

C₇₂H₉₆ClN₁₇O₁₄**paquinimodum**

paquinimod


N,5-diethyl-4-hydroxy-1-methyl-2-oxo-*N*-phenyl-1,2-dihydroquinoline-3-carboxamide

paquinimod

N,5-diéthyl-4-hydroxy-1-méthyl-2-oxo-*N*-phényl-1,2-dihydroquinoléine-3-carboxamide

paquinimod

N,5-dietil-4-hidroxi-1-metil-2-oxo-*N*-fenil-1,2-dihidroquinolina-3-carboxamida

C₂₁H₂₂N₂O₃**parogrelilum**

parogrelil


4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(pyridin-3-ylmethyl)=amino]pyridazin-3(2*H*)-one

parogrélil

4-bromo-6-[3-(4-chlorophényl)propoxy]-5-[(pyridin-3-ylméthyl)=amino]pyridazin-3(2*H*)-one

parogrelilo

4-bromo-6-[3-(4-clorofenil)propoxi]-5-[(piridin-3-ilmetil)=amino]piridazin-3(2*H*)-ona

C₁₉H₁₈BrClN₄O₂

pazopanibum


pazopanib

5-({4-[(2,3-dimethyl-2*H*-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide

pazopanib

5-[[4-[(2,3-diméthyl-2*H*-indazol-6-yl)méthylamino]pyrimidin-2-yl]amino]-2-méthylbenzènesulfonamide

pazopanib

5-({4-[(2,3-dimetil-2*H*-indazol-6-il)metilamino]pirimidin-2-il}amino)-2-metilbencenosulfonamidaC₂₁H₂₃N₇O₂S**relacatibum**


relacatib

N-[(1*S*)-3-methyl-1-[[[(4*S*,7*R*)-7-methyl-3-oxo-1-(pyridin-2-ylsulfonyl)=hexahydro-1*H*-azepin-4-yl]carbamoyl]butyl]-1-benzofuran-2-carboxamide

rélacatib

N-[(1*S*)-3-méthyl-1-[[[(4*S*,7*R*)-7-méthyl-3-oxo-1-(pyridin-2-ylsulfonyl)=hexahydro-1*H*-azépin-4-yl]carbamoil]butil]benzofurane-2-carboxamide

relacatib

N-[(1*S*)-3-metil-1-[[[(4*S*,7*R*)-7-metil-3-oxo-1-(piridin-2-ilsulfonyl)=hexahidro-1*H*-azepin-4-il]carbamoil]butil]-1-benzofuran-2-carboxamidaC₂₇H₃₂N₄O₆S**rilapladibum**

rilapladib



2-[2-[(2,3-difluorophenyl)methyl]sulfanyl]-4-oxoquinolin-1(4*H*)-yl)-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide

rilapladib

2-[2-[(2,3-difluorobenzyl)sulfanyl]-4-oxoquinoléin-1(4*H*)-yl]-*N*-[1-(2-méthoxyéthyl)pipéridin-4-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

rilapladib

2-[2-[(2,3-difluorobencil)sulfanil]-4-oxoquinolin-1(4*H*)-il]-*N*-[1-(2-metoxietil)piperidin-4-il]-*N*-[[4'-(trifluorometil)bifenil-4-il]metil]acetamida



rolipoltidum
rolipoltide


protein derived from two major allergens of *Cryptomeria japonica* pollen: Sugi basic protein (Cry j 1) and the polygalacturonase (Cry j 2):
(Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

rolipoltide

protéine dérivée de deux principaux allergènes de pollen du cèdre du Japon, *Cryptomeria japonica*, la protéine basique Sugi (Cry j 1) et la polygalacturonase (Cry j 2) :
(Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

rolipoltida

proteína derivada de dos de los alérgenos principales del polen del cedro de Japón, *Cryptomeria japonica* : la proteína básica Sugi (Cry j 1) y la poligalacturonasa (Cry j 2) :
(Cry j 1-(213-225)-peptidil)-L-arginil-L-arginil(Cry j 1-(108-120)-peptidil)-L-arginil-L-arginil(Cry j 2-(191-209)-peptidil)-L-arginil-L-arginil(Cry j 2-(88-107)-peptidil)-L-arginil-L-arginil(Cry j 1-(80-95)-peptidil)-L-arginil(Cry j 2-(75-89)-péptido)



```

MKVTVAFNQF  GPNRRVFIKR  VSNVIIHGRR  IDIFASKNFH  40
LQKNTIGTGR  RWKNNRIWLQ  FAKLTGFTLM  GRRLKMPMYI  80
AGYKTFDGRR  VDGIIAAYQN  PASWK                               105

```

romidepsinum
romidepsin



(1S,4S,10S,16E,21R)-7-[(2Z)ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

romidepsine

(1S,4S,7Z,10S,16E,21R)-7-éthylidène-4,21-bis(1-méthyléthyl)-2-oxa-12,13-dithia-5,8,20,23-tétraazabicyclo[8.7.6]tricos-16-ène-3,6,9,19,22-pentone

romidepsina

(1S,4S,10S,16E,21R)-7-[(2Z)etilideno]-4,21-diisopropil-2-oxa-12,13-ditia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-eno-3,6,9,19,22-pentona

**rotigaptidum**



rotigaptide

N-acetyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanylglycinamide

rotigaptide

acétyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanylglycinamide

rotigaptida

acetil-D-tirosil-D-prolil-(4*S*)-4-hidroxi-D-proliilglicil-D-alanilglicinamida**sapacitabinum**



sapacitabine

N-[1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl]hexadecanamide

sapacitabine

N-[1-(2-cyano-2-désoxy-β-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl]hexadécanamide

sapacitabina

N-[1-(2-ciano-2-desoxi-β-D-arabinofuranosil)-2-oxo-1,2-dihidropirimidin-4-il]hexadecanamida

simotaxelum

simotaxel


1,7β-dihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,10β,13α-tetrayl 4-acetate 2-benzoate 10-cyclopentanecarboxylate 13-[(2*R*,3*R*)-2-hydroxy-3-(isopropoxycarbonyl)amino]-3-(thiophen-2-yl)propanoate}

simotaxel

12b-acétate 12-benzoate 6-cyclopentanecarboxylate et 9-[(2*R*,3*R*)-2-hydroxy-3-[[[(1-méthyléthoxy)carbonyl]amino]-3-(thiophén-2-yl)propanoate] de (2*aR*,4*S*,4*aS*,6*R*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-4,11-dihydroxy-4*a*,8,13,13-tétraméthyl-5-oxo-2*a*,3,4,4*a*,5,6,9,10,11,12,12*a*,12*b*-dodécahydro-7,11-méthano-1*H*-cyclodéca[3,4]benz[1,2-*b*]oxète-6,9,12,12*b*-tétrayle

simotaxel

12b-acetato 12-benzoato 6-ciclopentanocarboxilato y 9-[(2*R*,3*R*)-2-hidroxi-3-[[[(1-metiletoxi)carbonil]amino]-3-(tiofen-2-il)propanoato] de (2*aR*,4*S*,4*aS*,6*R*,9*S*,11*S*,12*S*,12*aR*,12*bS*)-4,11-dihidroxi-4*a*,8,13,13-tetrametil-5-oxo-2*a*,3,4,4*a*,5,6,9,10,11,12,12*a*,12*b*-dodecahidro-7,11-metano-1*H*-ciclodeca[3,4]benz[1,2-*b*]oxeto-6,9,12,12*b*-tetrailo

C₄₆H₅₇NO₁₅S**sitagliptinum**

sitagliptin


(3*R*)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

sitagliptine

7-[(3*R*)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,2,4-triazolo[4,3-*a*]pyrazine

sitagliptina

7-[(3*R*)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-3-(trifluorometil)-5,6,7,8-tetrahidro-1,2,4-triazolo[4,3-*a*]pirazina

C₁₆H₁₅F₆N₅O

sontuzumabum

sontuzumab immunoglobulin G1, anti-(human episialin) (mouse monoclonal HMFG-1 γ 1-chain), disulfide with mouse monoclonal HMFG-1, dimer

sontuzumab immunoglobuline G1, anti-(épisialine, spécifique de l'épitope APDTR) ; dimère du disulfure entre la chaîne γ 1 et la chaîne légère de l'anticorps monoclonal de souris HMFG-1

sontuzumab inmunoglobulina G1, anti-(human episialina) dímero del disulfuro entre la cadena HMFG-1 γ 1 monoclonal de ratón y la cadena ligera HMFG-1 monoclonal de ratón


sotirimodum

sotirimod 2-methyl-1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-4-amine

sotirimod 2-méthyl-1-(2-méthylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphtyridin-4-amine

sotirimod 2-metil-1-(2-metilpropil)-1*H*-imidazo[4,5-*c*][1,5]naftiridin-4-amina

$C_{14}H_{17}N_5$

**stamulumabum***

stamulumab immunoglobulin G1, anti-(human growth differentiation factor 8) (human MYO-029 heavy chain), disulfide with human MYO-029 λ -chain, dimer

stamulumab immunoglobuline G1, anti-(facteur 8 de croissance/différenciation (GDF-8 ou myostatine) humain) ; dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain MYO-029

estamulumab inmunoglobulina G1, anti-(factor 8 de diferenciación del crecimiento humano) dímero del disulfuro entre la cadena pesada de MYO-029 humano y la cadena λ de MYO-029 humano

$C_{6330}H_{9748}N_{1672}O_{1998}S_{48}$

tadocizumabum*

tadocizumab immunoglobulin G1, anti-(human integrin α IIb β 3) Fab fragment (human-mouse monoclonal C4G1 γ 1-chain), disulfide with human-mouse monoclonal C4G1 κ -chain

tadocizumab immunoglobuline G1, anti-(intégrine α IIb β 3 humaine), disulfure entre la chaîne γ 1 et la chaîne κ du fragment Fab de l'anticorps monoclonal de souris C4G1 humanisé

tadocizumab

inmunoglobulina G1, anti-(integrina humana $\alpha\text{IIb}\beta 3$) disulfuro entre el fragmento Fab de la C4G1 cadena $\gamma 1$ del anticuerpo monoclonal hombre-ratón, y la cadena κ del anticuerpo monoclonal hombre-ratón C4G1

 $\text{C}_{2107}\text{H}_{3252}\text{N}_{562}\text{O}_{673}\text{S}_{12}$

		QVQLVQSGAE	VKKPGSSVKV
DIQMTQTPST	LSASVGDRVT	SCKASGYAFT	NYLIEWVRQA
ISCRASQDIN	NYLNWYQQKP	PGQGLEWIGV	IYPGSGGTNY
GKAPKLLIYY	TSTLHSGVPS	NEKFKGRVTL	TVDESTNTAY
RFSGSGSGTD	YTLTISSLQP	MELSSLRSED	TAVYFCARRD
DDFATYFCQQ	GNTLPWTFGQ	GNYGWFAYWG	QGTLVTSSA
GTKVEVKRTV	AAPSVFIFPP	STKGPSVFPL	APSSKSTSGG
SDEQLKSGTA	SVVCLLNNFY	TAALGCLVKD	YFPEPVTVSW
PREAKVQWKV	DNALQSGNSQ	NSGALTSGVH	TFPAVLQSSG
ESVTEQDSKD	STYSLSSLT	LYSLSSVTV	PSSSLGTQTY
LSKADYEKHK	VYACEVTHQG	ICNVNHKPSN	TKVDKKVEPK
LSSPVTKSFN	RGEC	SCDKTH	

talotrexinum
talotrexin


2-[[[(4S)-4-carboxy-4-[(2,4-diaminopteridin-6-yl)methyl]=amino]benzamido)butyl]carbamoil]benzoic acid

talotrexine

acide 2-[[[(4S)-4-carboxy-4-[[[(2,4-diaminoptéridin-6-yl)méthyl]=amino]benzoyl]amino]butyl]carbamoil]benzoïque

talotrexina

ácido 2-[[[(4S)-4-carboxi-4-[[[(2,4-diamino-6-pteridinil)metil]=amino]benzoil]amino]butil]carbamoil]benzoico

 $\text{C}_{27}\text{H}_{27}\text{N}_9\text{O}_6$


telaprevirum
telaprevir



(1S,3aR,6aS)-2-[(2S)-2-[(2S)-cyclohexyl[(pyrazin-2-ylcarbonyl)amino]acetamido]-3,3-dimethylbutanoyl]-N-[(3S)-1-cyclopropylamino]-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide

telaprévir

(1S,3aR,6aS)-2-[(2S)-2-[(2S)-cyclohexyl[(pirazinilcarbonyl)amino]=étyl]amino]-3,3-diméthylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)=oacétyl]butyl]octahydrocyclopenta= [c]pyrrole-1-carboxamide

telaprevir

1S,3aR,6aS)-2-[(2S)-2-[(2S)-ciclohexil[(pirazinilcarbonyl)amino]=acetil]amino]-3,3-dimetilbutanoil]-N-[(1S)-1-[(ciclopropilamino)=oxoacetil]butil]octahidrociclopenta[c]pirrol-1-carboxamida

**tiplasininum**



tiplasinin

2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1*H*-indole-3-yl]-2-oxoacetic acid

tiplasinine

acide [1-benzyl-5-[4-(trifluorométhoxy)phényl]-1*H*-indol-3-yl]oxoacétique

tiplasinina

ácido 2-{1-bencil-5-[4-(trifluorometoxi)fenil]-1*H*-indol-3-il]-2-oxoacético**tramiprosatum**

tramiprosate



3-aminopropane-1-sulfonic acid

tramiprosate

acide 3-aminopropane-1-sulfonique

tramiprosato

ácido 3-aminopropano-1-sulfónico

**transferrinum aldifitoxum**

transferrin aldifitox


a conjugate of the precursor of human serotransferrin (siderophillin) with a primary amine group used to form an amidine with (4-aminobutane-1,4-diyl)sulfanediyl[(3*RS*)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an *N*-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from *Corynebacterium diphtheriae*-(26-560)-peptide

transferrine aldifitox

précurseur de la sérotransferrine humaine (sidérophilline) dont une fonction amine primaire est liée par une fonction carboximidamide (amidine) au pont (4-aminobutane-1,4-diyl)sulfanediyl[(3*RS*)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phénylénecarbonyl lui-même lié par une fonction benzamide à une amine primaire du [550-L-phénylalanine]toxine diphtérique de *Corynebacterium diphtheriae*-(26-560)-peptide

transferrina aldifitox

precursor de la serotransferrina humana (siderofilina) en el cual una función amina primaria está ligada por una función carboximidamida (amidina) al puente (4-iminobutano-1,4-diil)sulfanodiil[(3RS)-2,5-dioxopirrolidina-1,3-diil]-1,3-fenilenocarbonil ligado a su vez por una función benzamida una amina primaria de la [550-L-fenilalanina]toxina diftérica del *Corynebacterium diphtheriae*-(26-560)-péptido

C₅₉₉₂H₉₃₁₇N₁₆₄₁O₁₈₃₄S₆₃

H₂N-CRM107=

GADDVVDSSK	SFVMENFSSY	HGTPGYVDS	IQKGIQPKKS
GTQGNYYDDW	KGFYSTDNKY	DAAGYSVDNE	NPLSGKAGGV
VKVTPGLTK	VLALKVDNAE	TIKKELGLSL	TEPLMEQVGT
EEFIKRFQDG	ASRVVLSLPF	AEGSSSVEYI	NNWEQAKALS
VELEINFETR	GKRGQDAME	YMAQACAGNR	VRRSVGSSLS
CINLDWDVIR	DKTKTKIESL	KEHGPIKNKM	SESPNKTVSE
EKAKQYLEEF	HQTALHPEL	SELKTVTGTN	PVFAGANYAA
WAVNVAQVID	SETADNLEKT	TAALSILPGI	GSVMGIADGA
VHHNTEEIVA	QSIALSSLMV	AQAIPLVGEL	VDIGFAAYNF
VESIINLFQV	VHNSYNRPAY	SPGHKTQPFL	HDGYAVSWNT
VEDSIIRTGF	QGESGHDIKI	TAENTPLPIA	GVLLPTIPGK
LDVNSKSTHI	SVNGRKIRM	CRAIDGDTVTF	CRPKSPVYVG
NGVHANLHVA	FHRSSSEKIH	SNEISSDSIG	VLGYQKTVDH
TKVNFKLSLF	FEIKS		

tucotuzumabum celmoleukinum*

tucotuzumab celmoleukin

immunoglobulin G1, anti-(tumor associated calcium signal transducer 1 (KS 1/4 antigen)) (human-mouse monoclonal huKS-IL2 heavy chain) fusion protein with interleukin 2 (human), disulfide with human-mouse monoclonal huKS-IL2 light chain, dimer

tucotuzumab celmoleukine

immunoglobuline G1, anti-(transducteur 1 du signal calcique associé aux cellules tumorales humaines), dimère du disulfure entre le peptide de fusion de la chaîne lourde, de l'anticorps monoclonal de souris huKS-IL2 humanisé, avec l'interleukine 2 humaine, et la chaîne légère de l'anticorps monoclonal de souris huKS-IL2 humanisé

tucotuzumab celmoleukina

inmunoglobulina G1, anti-(antígeno 17-1A humano) dímero del disulfuro entre la proteína de fusión de la cadena pesada del anticuerpo monoclonal huKS-IL2 hombre-ratón y la interleukina 2 (humana), y la cadena ligera del anticuerpo monoclonal huKS-IL2 hombre-ratón

 $C_{7812}H_{12114}N_{2042}O_{2406}S_{60}$
velaferminum*

velafermin

fibroblast growth factor 20 (human recombinant CG53135)

vélafermine

facteur-20 de croissance du fibroblaste humain recombinant (CG53135)

velafermina

factor 20 de crecimiento de fibroblastos (recombinante humano CG53135)

 $C_{1047}H_{1632}N_{306}O_{302}S_5$

MAPLAEVGGF LGGLEGLGQQ VGSFLLPPA GERPPLLGER
 RSAAERSARG GPGAAQLAHL HGILRRRQLY CRTGFHLQIL
 PDGSVQGTTRQ DHSLEFGILEF ISVAVGLVSI RGVDSGLYL
 MNDKGELYGS EKLTSECIFR EQFEENWYNT YSSNIYKHGD
 TGRRYFVALN KDGTPRDGAR SKRHQKFTHF LPRPVDPERV
 PELYKDLLMY T

verpasepum caltespenum*

verpasepum caltespen


60 kDa chaperonin 2 (HSP 65 from *Mycobacterium bovis* strain BCG) fusion protein with L-histidylprotein E7 from human papillomavirus type 16

verpasepum caltespen

60 kDa chaperonine 2 (HSP 65 de *Mycobacterium bovis* souche BCG) protéine de fusion avec la L-histidylprotéine E7 de papillomavirus de type 16 humain

verpasepum caltespeno

60 kDa chaperonina 2 (HSP 65 de *Mycobacterium bovis* cepa BCG) proteína de fusión con la L-histidilproteína E7 del papilomavirus humano 16



AKTIAYDEEA	RRGLERGLNA	LADAVKVTLG	PKGRNVVLEK
KWGAPTITND	GVSIAKEIEL	EDPYEKIGAE	LVKEVAKKTD
DVAGDGTTTA	TVLAQALVRE	GLRNVAAGAN	PLGLKRGIEK
AVEKVTETLL	KGAKEVETKE	QIAATAAISA	GDQSIGDLIA
EAMDKVGNEG	VITVEESNTF	GLQLELTEGM	RFDKGYISGY
FVTDPERQEA	VLEDPYILLV	SSKVSTVKDL	LPLLEKVIGA
GKPLLIIAED	VEGEALSTLV	VNKIRGTFKS	VAVKAPGFGD
RRKAMLQDMA	ILTGGQVISE	EVGLTLENAD	LSLLGKARKV
VVTKDETTIV	EGAGDTDAIA	GRVAQIRQEI	ENSDDSDYRE
KLQERLAKLA	GGVAVIKAGA	ATEVELKERK	HRIEDAVRNA
KAAVEEGIVA	GGGVTLQAA	PTLDELKLEG	DEATGANIVK
VALEAPLKQI	AFNSGLEPGV	VAEKVRNLPA	GHGLNAQTGV
YEDLLAAGVA	DPVKVTRSAL	QNAASIAGLF	LTTEAVVADK
PEKEKASVPG	GGDMGGMDFH	MHGDTPTLHE	YMLDLQPETT
DLYCYEQLND	SSEEEDEIDG	PAGQAEPDRA	HYNIVTFCKK
CDSTLRLCVQ	STHVDIRTLE	DLLMGTLGIV	CPICSQKP

vicrivirocum
vicriviroc



(4,6-dimethylpyrimidin-5-yl){4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}methanone

vicriviroc

1-[(4,6-diméthylpyrimidin-5-yl)carbonyl]-4-[(3S)-4-[(1R)-2-méthoxy-1-[4-(trifluorométhyl)phényl]éthyl]-3-méthylpipérazin-1-yl]-4-méthylpipéridine

vicriviroc

(4,6-dimetilpirimidin-5-il){4-[(3S)-4-[(1R)-2-metoksi-1-[4-(trifluorometil)fenil]etil]-3-metilpiperazin-1-il]-4-metilpiperidin-1-il}metanona



vorinostat
vorinostat



N-hydroxy-*N'*-phenyloctanediamide

vorinostat

N-hydroxy-*N'*-phényloctanediamide

vorinostat

N-hidroxi-*N'*-feniloctanodiamido

**zibotentanum**

zibotentan



N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

zibotentan

N-(3-méthoxy-5-méthylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phényl]pyridine-3-sulfonamide

zibotentán

N-(3-metoxi-5-metilpirazin-2-il)-2-[4-(1,3,4-oxadiazol-2-il)fenil]piridine-3-sulfonamida

**zotarolimusum**

zotarolimus



(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-10,21-dimethoxy-3-[(2*R*)-1-[(1*S*,3*R*,4*S*)-3-methoxy-4-(1*H*-tetrazol-1-yl)cyclohexyl]propan-2-yl]-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadecahydro-5*H*-23,27-epoxy-2,1-*c*[1,4]oxazahentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

zotarolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-10,21-diméthoxy-3-[(1*R*)-2-[(1*S*,3*R*,4*S*)-3-méthoxy-4-(1*H*-tétrazol-1-yl)cyclohexyl]-1-méthyléthyl]-6,8,12,14,20,26-hexaméthyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadécahydro-23,27-époxy-5*H*-pyrido[2,1-*c*][1,4]oxazahentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

zotarolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihidroxi-10,21-dimetoxi-3-[(2*R*)-1-[(1*S*,3*R*,4*S*)-3-metoxi-4-(1*H*-tetrazol-1-il)ciclohexil]propan-2-il]-6,8,12,14,20,26-hexametil-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadecahidro-5*H*-23,27-epoxipirido[2,1-*c*][1,4]oxazahentriacontina-1,5,11,28,29(6*H*,31*H*)-pentona



- * Electronic structure available on Mednet: <http://mednet.who.int/>
- * Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- * Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 21
Dénominations communes internationales recommandées (DCI Rec.): Liste 21
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 21
(WHO Drug Information, Vol. 35, No. 5, 1981)

p. 4	<i>delete/supprimer/suprimase</i>	<i>insert/insérer/insertése</i>
	docusatum natriicum	natrii docusas

Recommended International Nonproprietary Names (Rec. INN): List 54
Dénominations communes internationales recommandées (DCI Rec.): Liste 54
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 54
(WHO Drug Information, Vol. 19, No. 3, 2005)

p. 253	<i>suprimase</i>	<i>insertése</i>
	epoetina zeta	epoetina dseta

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.